<- Go Home
Abcam Limited
Abcam Limited, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company’s principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. Abcam Limited was formerly known as Abcam plc and changed its name to Abcam Limited in December 2023. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam Limited operates as a subsidiary of Danaher Corporation.
Market Cap
$4.4B
Volume
720.8K
Cash and Equivalents
$79.0M
EBITDA
$106.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$288.1M
Profit Margin
75.88%
52 Week High
$20.10
52 Week Low
$9.91
Dividend
N/A
Price / Book Value
6.07
Price / Earnings
1.8K
Price / Tangible Book Value
36.31
Enterprise Value
$4.5B
Enterprise Value / EBITDA
38.59
Operating Income
$73.0M
Return on Equity
0.35%
Return on Assets
4.36
Cash and Short Term Investments
$79.0M
Debt
$217.0M
Equity
$719.2M
Revenue
$379.7M
Unlevered FCF
$34.6M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium